Trial Profile

A single agent trial of FLX 787 for treatment of cramps associated with amyotrophic lateral sclerosis (ALS)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FLX 787 (Primary)
Indications Amyotrophic lateral sclerosis; Cramp
Focus Therapeutic Use
Sponsors Flex Pharma

Most Recent Events

06 Nov 2017 According to a Flex Pharma media release, the study was terminated early to focus the Companys resources on the ongoing US Phase 2b ALS study (COMMEND).
06 Nov 2017 Results (n=8) presented in a Flex Pharma media release.
02 Aug 2017 According to a Flex Pharma media release, the company expects important data readouts from this study in 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com